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Vaccine safetyInformation provided by most influenza vaccine manufacturers do not reflect the recommendations of
WHO and/or national public health advisory groups with regard to the use of influenza vaccines in preg-
nant or lactating women. The majority of vaccines contain precautionary language which could discour-
age use in pregnant women and some include stronger language discouraging or contradicting use in
pregnant or lactating women. Regulators and manufacturers should regularly assess the language of
pregnancy and lactation sections in product information for vaccines and include information from
national public health advisory groups regarding use by pregnant or lactating women and data from rel-
evant studies.
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The World Health Organization, the U.S. Centers for Disease
Control and Prevention [1], and the Public Health Agency of Canada
[2] recommend that pregnant women be given high priority for
seasonal influenza vaccination. Maternal influenza immunization
has the potential to reduce disease during early childhood by pre-
venting disease in newborns through trans-placental transfer of
antibodies [3]. Based on the substantial risk of severe disease inneonates and the safety of influenza vaccine during pregnancy,
the WHO recommends that pregnant women should be immu-
nized at any stage during pregnancy [4,5]. In 2014, theWHO Global
Advisory Committee on Vaccine Safety, in a safety review of inac-
tivated influenza vaccine given during pregnancy, found no safety
signals, although most of the data was from vaccination in the
second and third trimester [6]. Several recent systematic reviews
re-confirmed these findings of no safety signals [7–9]. Most of
the available data are from studies of women who were known
to be pregnant at the time of vaccination. One unpublished study
in the United States has suggested a possible signal of increased
spontaneous abortion when vaccine was administered very early
Table 1
Summary information for influenza vaccine product information for pregnant
women.
Category Seasonal Pandemic Total
Pregnancy Information 65 31 96
Can be used 9 (14%) 1 (3%) 10 (10%)
Not recommended or forbidden 3 (5%) 1 (3%) 4 (4%)
Administer with caution 1 (2%) 0 1 (1%)
After first trimester 1a (2%) 0 1 (1%)
Health care provider to assess 29a (45%) 19 (61%) 48 (50%)
If benefits outweigh risks 1 (2%) 0 1 (1%)
If clearly needed 17 (26%) 9 (29%) 26 (27%)
No data 1 (2%) 1 (3%) 2 (2%)
Not applicable 3 (5%) 0 3 (3%)
a For those at high risk the recommendation is for any stage of pregnancy (1 in
category ‘after first trimester’ and 2 in ‘health care provider to assess’).
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reviews and they usually require data on the individual products to
support package product information. National and international
technical advisory groups often make recommendations consider-
ing all products, such as inactivated influenza vaccines, to be sim-
ilar unless there are data indicating otherwise. Additional studies
are indicated with different products where data are lacking, but
the abundance of evidence clearly indicates a substantial benefit
from multiple inactivated influenza vaccines for women who are
known to be pregnant. In spite of recommendations for pregnant
women to receive influenza vaccines, maternal influenza immu-
nization rates remain low in many countries [4].
Identification of barriers to influenza vaccine uptake is relevant
for policy makers who wish to increase acceptance of vaccines in
pregnant women. Health care providers can affect use in pregnant
women who are cautious about vaccinations because they are
assuming responsibility for their life and that of their fetus
[11,12]. As pregnancy is often an exclusion criterion in clinical tri-
als, the availability of adequate and well-controlled, product speci-
fic clinical data is limited [13] and safety information for influenza
vaccines is mainly based on observational study and post-licensure
surveillance data [14]. Language in vaccine product information is
therefore formulated based on precautionary principles by regula-
tors and pharmaceutical companies [15]. Overly cautionary and/or
restrictive language in vaccine information regarding use in preg-
nant and/or lactating women could be an obstacle to the use of
influenza vaccine. The use of standardized fact-based information
is critical to avoid misperceptions in the various audiences reading
the product information. The objective of this review was to deter-
mine the degree of variability of the wording of influenza vaccine
product information for descriptions of use by pregnant and lactat-
ing women.
Product information in the European Union is called Summary
of Product Characteristics and generally has detailed information
to the prescriber. Package Inserts are the United States equivalent
and typically contain detailed safety information from clinical tri-
als [16]. We use ‘‘product information” to describe this material
provided by the manufacturer and approved by the regulator
regarding use of influenza vaccines, including package inserts,
package labels, package leaflets, patient information labeling, pro-
duct description and summary of patient characteristics.2. Methods
In a previous review [17] we identified 108 influenza vaccines
marketed in recent years. Types of influenza vaccines recently pro-
duced include live and inactivated, monovalent, bivalent, trivalent,
or quadrivalent preparations, whole virion, split-virus (with or
without adjuvants), surface antigen, and virosomal. We identified
the vaccines where product information was still available online.
We also searched online through the Food and Drug Administra-
tion (www.fda.gov), the European Medicines Agency site (www.
ema.europa.eu/ema), and the widely used internet search engine,
Google (www.google.com) for product information for influenza
vaccines. We attempted to find the most recent product informa-
tion for seasonal, pandemic and pre-pandemic influenza vaccines.
When information was found for the same vaccine produced in dif-
ferent years, only information for the most recently produced vac-
cine was included. Vaccines marketed under different names in
different countries were listed under each different name.
We identified products with information written in English and
available online. The product information was searched for the
words ‘‘pregnant”, ‘‘pregnancy”, ‘‘lactating” and ‘‘lactation” for per-
tinent information regarding the use of the vaccine in pregnantand/or lactating women. Information was identified for influenza
vaccines in other languages but we did not conduct searches
in other languages. For example, some influenza vaccine
manufacturer websites were available with information translated
into English but offered only non-English product information.
There are likely additional products with information in countries
with no English language information available. For vaccines with
product information in a language other than English, we used
Google translate (translate.google.com) to translate the words
‘‘pregnant”, ‘‘pregnancy”, ‘‘lactating” and ‘‘lactation” from English
to the language of the prescribing information and then searched
the product information for pertinent text regarding the use of
the vaccine in pregnant and/or lactating women. We also trans-
lated the word ‘‘age” from English to find information regarding
approved ages for use.3. Results
3.1. Information on use during pregnancy
We identified product information for 96 influenza vaccines; 31
pre- or pandemic (H1N1 and H5N1) and 65 seasonal vaccines
(Table 1). Twenty vaccines (21%) had language suggesting that,
when considering for use in pregnant women, official recommen-
dations should be taken into account; 16 were in product informa-
tion for pandemic influenza vaccines and 4 were for seasonal
vaccines.
One-half (48) of the vaccines had product information with
language suggesting that users consult a health care provider to
determine whether the vaccine should be administered during
pregnancy. The next most common category (27%) was vaccines
with information suggesting use ‘‘if clearly needed” without fur-
ther explanation of ‘‘clearly needed”. Two vaccines that had infor-
mation recommending that a health care provider assess the
situation also noted that people in high risk groups should receive
the vaccine at any stage of pregnancy.
Only 10 of the vaccines had product information that suggested
use during pregnancy: one from Australia, one from Canada, one
from East Asia, and the remaining 7 were from EU countries.
Among these 10 vaccines, there was a wide variety of information
regarding safety data and what stage of pregnancy was preferred.
One vaccine’s information indicated that influenza vaccines can
be used throughout pregnancy. Seven vaccines included product
information stating that inactivated influenza vaccines can be used
in all stages of pregnancy and included statements that safety data
from worldwide use do not show attributable adverse events in
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able from use in the second and third trimester than first trimester.
Information for one vaccine suggested use after the first trimester.
Product information from another vaccine recommends influenza
vaccine ‘‘to pregnant women who will be in the second or third
trimester during the influenza season, including those in the first
trimester at the time of vaccination” and further indicates that
the vaccine has not been evaluated in pregnant women. Product
information from another vaccine suggests that unadjuvanted vac-
cine has a long history of safe use in pregnant women and is there-
fore preferred, but that the specific vaccine has not been studied in
pregnant women.
Product information from 4 vaccines indicated that influenza
vaccine should not be used in pregnant women: 2 were formula-
tions licensed in some EU countries [one is no longer authorized
for use], the others were used in two large developing countries.
The wording of one of the EU country vaccine product information
indicated that it was ‘not recommended during pregnancy’. Among
the developing country vaccines, one was ‘not recommended to
pregnant or lactating women’, the other lists ‘women during preg-
nancy’ among the groups who are forbidden to use the product.
At the time of this study, 19 of the 96 vaccines we identified
were approved for use in the United States and all included word-
ing indicating that the vaccine ‘should be given to a pregnant
woman only if clearly needed’, including 11 vaccines indicating
Pregnancy Category B (animal studies have been performed) and
8 vaccines indicating Pregnancy Category C (no animal studies
have been conducted). The US FDA is changing the categories,
effective June 30, 2015 [18], and future package inserts will include
information regarding infertility and pregnancy registries; it is
unclear how these changes will affect the product information
for use in pregnancy and lactation reported here.
The wording in package information differed for seasonal and
pandemic vaccines. Of the 65 seasonal vaccines, 9 (14%) indicated
the vaccines could be used in pregnancy, 29 (45%) indicated use if a
consulted health care provider recommends the vaccine and 17
(26%) indicated ‘if clearly needed’.
Of the pre- and pandemic vaccines, 19/31 (61%) indicated they
were recommended for use in pregnancy if a health care provider
decided, 9 (29%) indicated ‘if clearly needed’. Recommendations
against use by pregnant women were found for only 1 of the 31
pre-pandemic vaccines.3.2. Information on use during breastfeeding
We found information concerning vaccination of lactating
women for 90 of the 96 influenza vaccines (information for 6 vac-
cines did not mention breastfeeding or lactation) (Table 2). Nearly
half of the product information indicated that influenza vaccine
can be used by breastfeeding mothers. Only four vaccines (all were
for pandemic influenza) had language suggesting that, whenTable 2
Summary information for influenza vaccine product information for women who are
breastfeeding.
Category Seasonal Pandemic Total
Breastfeeding Information 65 31 96
Can be used 33 (51%) 12 (39%) 45 (47%)
Not recommended 2 (3%) 1 (3%) 3 (3%)
Health care provider to assess 3 (5%) 6 (19) 9 (9%)
If benefits outweigh risks 2 (3%) 1 (3%) 3 (3%)
If necessary 0 2 (6%) 2 (2%)
Use with caution 15 (23%) 6 (19%) 21 (22%)
No data available 3 (5%) 1 (3%) 4 (4%)
NA 3 (5%) 0 3 (3%)
Breastfeeding not mentioned 4 (6%) 2 (6%) 6 (6%)considering for use in lactating women, official recommendations
should be taken into account.4. Discussion
Despite the favorable risk-benefit profile for influenza vaccina-
tion of pregnant and lactating women recommended by WHO,
many governments, obstetricians, and expert groups [4,5,19], pro-
duct information for some vaccines limit or even contraindicate
the use of influenza vaccines in pregnant women. Contraindica-
tions are usually given only if the risk to pregnancy or the develop-
ing fetus significantly outweighs the potential benefit to the
mother or the fetus [19]. Adding contraindications to product
information not only prohibits the vaccine’s use in the country of
manufacture, but has discouraging effects on importing countries
where favorable vaccination policies are in place.
Misperceptions and lack of awareness regarding influenza vac-
cine efficacy and safety have been identified as barriers to vaccina-
tion among health care providers [20–22]. Statements such as
‘administer with caution’ do not provide added scientific or practi-
cal information on the use of the vaccine and may cause misper-
ceptions. Similarly, product information with many vaccines
include cautionary language such as ‘if the benefits outweigh the
risks’, or ‘your doctor needs to assess the benefits and potential
risks of giving you the vaccine if you are pregnant’. Such state-
ments do not resolve complex accountability issues for the vaccine
but suggest a shifting of responsibility from manufacturers and
regulators to healthcare providers. They may be perceived by
healthcare providers as additional deterrent to recommending
and administering influenza vaccine to pregnant and lactating
women [23].
The study was limited to the product information available
online, likely skewing the results toward high resource countries
with widespread internet use. Online information in languages
other than English or from websites that did not provide English
translations were also not included. It is unclear from our study
what information is included in non-English product information
regarding use during pregnancy or lactation. Our review reveals a
considerable variability in the language used in product informa-
tion and show that few products reference the current public
health recommendations. It could be useful to study package
inserts in Russian, Mandarin, etc. to see if results are similar.
Further studies are indicated to determine the factors that con-
tribute to low immunization coverage rates in pregnant women,
including understanding by healthcare providers of the benefits
to the mother, the developing fetus, and the infant in the first
fewmonths after birth [24]. The evidence resulting from such stud-
ies could help inform and optimize educational interventions tar-
geting health care workers recommending or giving influenza
vaccines to pregnant women [25,26]. Also, there are differences
in influenza vaccines that could affect safety [17], and many vacci-
nes do not specify that studies have been done in pregnant women
indicating the need for additional studies to assess safety in early
pregnancy.
Typically, the format and content of vaccine product informa-
tion is defined by law. Manufacturers propose the wording and
the information is approved by the relevant national regulatory
authority. Assuming that product information must not be false
or misleading and must not contain implied claims or uses for
which there is inadequate evidence [27], updating product infor-
mation language to include recent safety studies and reviews
should be considered by manufacturers and regulators. In the
absence of safety data for specific products, manufacturers and
public health authorities should generate additional safety data
for use of these products by pregnant women. We do not believe
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enza vaccines in lactating women.
Regulators from several countries in the European Union and
the US Food and Drug Administration (US FDA) have started to
address content issues related to package inserts (the term used
by US FDA) for vaccine use in pregnant women.
WHO is working with regulators and manufacturers to support
evidence-based use of vaccines during pregnancy by reviewing the
wording in product information for several vaccines and is devel-
oping a guidance document to help interpret information in preg-
nancy subsections of product information for inactivated influenza
vaccines [27]. Such complementary information may help health-
care providers understand the benefits as well as the available data
on the safety of influenza vaccines during pregnancy and mothers
who are breastfeeding [28]. More well-definedWHO recommenda-
tions or guidelines could conflict with national legal requirements
for the format of a product information.
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